<DOC>
	<DOCNO>NCT01523093</DOCNO>
	<brief_summary>The purpose study compare single-dose oral bioavailability Ondansetron 8 mg orally disintegrate tablet OHM Laboratories Inc ( A subsidiary Ranbaxy Pharmaceuticals Inc , USA ) Zofran ODT® 8 mg orally disintegrate tablet GlaxoSmithKline , USA healthy , adult , human , male subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , two-period , two-sequence , single-dose , crossover bioavailability study compare Ondansetron 8 mg orally disintegrate tablet OHM Laboratories Inc ( A subsidiary Ranbaxy Pharmaceuticals Inc , USA ) Zofran ODT® orally disintegrate tablet ( contain 8 mg ondansetron ) GlaxoSmithKline healthy , adult , human , male subject fast condition . During period study overnight fast least 10 hour , single oral dose either test reference product administer placing tablet tongue till dissolve swallow use 240 mL drinking water ambient temperature supervision medical officer . During course study , safety parameter include vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical , serology parameter urine analysis ) assess laboratory parameter hematology biochemistry repeat end study .</detailed_description>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Were age range 1845 year . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . Had history allergy hypersensitivity ondansetron , relate drug serotonin receptor blocker drug . Had history dizziness , seizures extrapyramidal symptom . Had history urticarial reaction rash exposure drug . Had history anaphylaxis angina ( chest pain ) . Had history hepatitis , constipation phenylketonuria . Had history recurrent episodes headache . Had history bronchospasm , asthma shortness breath . Had history hiccup . Had evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Had presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Had presence value significantly different normal reference range and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . Was positive urinary screen test drug abuse ( opiates cannabinoids ) Had presence value significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Had clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , epithelial cell ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Had clinically abnormal ECG Chest Xray . Had history serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes glaucoma . Had history psychiatric illness , might impair ability provide write informed consent . Was regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . Had history drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Used enzyme modify drug within 30 day prior Day 1 study . Had participate clinical trial within 12 week precede Day 1 study . Subjects , completion study , donate and/or lose 350 mL blood past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>